content: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(d) OF
                             THE SECURITIES ACT OF 1934
  
           Date of report (Date of earliest event reported): June 4, 2002
                                                             ------------
  
  
                                 CYTOGEN CORPORATION
                                 -------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
            Delaware                      000-14879               222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction     (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  
  600 College Road East, CN 5308, Princeton, NJ                         08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                            (Zip Code)
  
  
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
  
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  <PAGE>
  
  
           Item 5.     Other Events.
  
           On June 4, 2002, Cytogen Corporation (the "Company")  announced that it
  had issued and sold 4,166,700  shares (the "Shares") of its common stock,  $0.01
  par value per share, to the State of Wisconsin  Investment  Board ("SWIB"),  the
  Company's largest current shareholder, at a price of $1.20 per share. The Shares
  were registered under the Company's existing Registration  Statement on Form S-3
  (File No. 333-72226) (the "Registration  Statement"),  which permits the Company
  to issue up to an  aggregate  of  10,000,000  shares  of  common  stock  and was
  declared effective by the Securities and Exchange  Commission (the "Commission")
  on November 5, 2001.  On June 4, 2002,  the  Company  filed a second  prospectus
  supplement to the  prospectus  dated as of October 25, 2001 with the  Commission
  relating to such  issuance  and sale of Shares to SWIB.  The Company  previously
  issued 2,970,665  registered  shares of common stock to SWIB on January 22, 2002
  under the Registration Statement.
  
           A copy of the Company's press release  announcing the issuance and sale
  of the Shares to SWIB is  attached  hereto as Exhibit  99.1 and is  incorporated
  herein  by  reference.  The  foregoing  description  of such  press  release  is
  qualified in its entirety by reference to such document.
  
           Item 7.     Financial Statements, Pro Forma Financial Information and
  Exhibits.
  
           (c) Exhibits.
  
                  Exhibit No.      Description
                  -----------      -----------
  
                     99.1          Press Release, dated June 4, 2002, issued by
                                   the Company
  
  
  <PAGE>
  
  
  
                                     SIGNATURES
  
  
                    Pursuant to the requirements of the Securities Exchange Act of
  1934,  the  registrant has duly caused this report to be signed on its behalf by
  the undersigned hereunto duly authorized.
  
  
                                                Cytogen Corporation
  
  
  
                                                By: /s/ Lawrence R. Hoffman
                                                   -------------------------------
                                                   Lawrence R. Hoffman,
                                                   Chief Financial Officer
  
  
  Date:  June 4, 2002
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8-ktext_060402.txt", "description": "FORM 8-K DATED JUNE 4, 2002", "secsgml_size_bytes": 3929}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "02670176"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(d) OF
                             THE SECURITIES ACT OF 1934
  
           Date of report (Date of earliest event reported): June 4, 2002
                                                             ------------
  
                                 CYTOGEN CORPORATION
                                 -------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                      000-14879               222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction     (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  600 College Road East, CN 5308, Princeton, NJ                         08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                            (Zip Code)
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  Item 5.     Other Events.
  
           On June 4, 2002, Cytogen Corporation (the "Company")  announced that it
  had issued and sold 4,166,700  shares (the "Shares") of its common stock,  $0.01
  par value per share, to the State of Wisconsin  Investment  Board ("SWIB"),  the
  Company's largest current shareholder, at a price of $1.20 per share. The Shares
  were registered under the Company's existing Registration  Statement on Form S-3
  (File No. 333-72226) (the "Registration  Statement"),  which permits the Company
  to issue up to an  aggregate  of  10,000,000  shares  of  common  stock  and was
  declared effective by the Securities and Exchange  Commission (the "Commission")
  on November 5, 2001.  On June 4, 2002,  the  Company  filed a second  prospectus
  supplement to the  prospectus  dated as of October 25, 2001 with the  Commission
  relating to such  issuance  and sale of Shares to SWIB.  The Company  previously
  issued 2,970,665  registered  shares of common stock to SWIB on January 22, 2002
  under the Registration Statement.
  
           A copy of the Company's press release  announcing the issuance and sale
  of the Shares to SWIB is  attached  hereto as Exhibit  99.1 and is  incorporated
  herein  by  reference.  The  foregoing  description  of such  press  release  is
  qualified in its entirety by reference to such document.
  
           Item 7.     Financial Statements, Pro Forma Financial Information and
  Exhibits.
  
           (c) Exhibits.
  
                  Exhibit No.      Description
                  -----------      -----------
  
                     99.1          Press Release, dated June 4, 2002, issued by
                                   the Company
  SIGNATURES
  
                    Pursuant to the requirements of the Securities Exchange Act of
  1934,  the  registrant has duly caused this report to be signed on its behalf by
  the undersigned hereunto duly authorized.
  
                                                Cytogen Corporation
  
                                                By: /s/ Lawrence R. Hoffman
                                                   -------------------------------
                                                   Lawrence R. Hoffman,
                                                   Chief Financial Officer
  
  Date:  June 4, 2002